Real world experience with [68Ga]PentixaFor PET/CT in Primary Aldosteronism using newly developed harmonized diagnostic criteria
[<sup>68</sup>Ga]PentixaFor PET continues to show promise for non-invasive PA subtyping. Harmonized interpretation criteria substantially improved inter-reader agreement. When combined with (partial) AVS, PET increases diagnostic confidence and may expand access to definitive treatment. Further studies are warranted to validate the proposed PET interpretation criteria and better define the subset of patients in whom [<sup>68</sup>Ga]PentixaFor PET/CT alone might suffice for PA subtyping.
Authors
- Mark Gurnell
- Frederike Butz (ORCID: https://orcid.org/0000-0002-5963-1558)
- Federico Collettini (ORCID: https://orcid.org/0000-0001-5378-461X)
- Martina T. Mogl (ORCID: https://orcid.org/0000-0002-3676-047X)
- James MacFarlane (ORCID: https://orcid.org/0000-0001-6937-2775)
- Dominik Spira (ORCID: https://orcid.org/0000-0001-8913-1645)
- Lukas Maurer (ORCID: https://orcid.org/0000-0002-5813-7910)
- Linus Haberbosch (ORCID: https://orcid.org/0000-0002-4464-0427)
- Daniel Gillett (ORCID: https://orcid.org/0000-0002-9773-6502)
- Anna Herden
- Tina Kienitz (ORCID: https://orcid.org/0000-0003-4637-0405)
- L Richter
- Knut Mai
- Dominik Soll
- Sophie Howarth
- Linus Hesse
- Christian J. Strasburger
Institutions
- Schott (Germany) (DE)
- National Institute for Health and Care Research (GB)
- Humboldt-Universität zu Berlin (DE)
- German Institute of Human Nutrition (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.3389/fendo.2026.1787233
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00